The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 26, 2012
Filed:
Nov. 23, 2010
Seong Heon Kim, Livington, NJ (US);
Gopinadhan N. Anilkumar, Edison, NJ (US);
Michael K. C. Wong, North Brunswick, NJ (US);
Qingbei Zeng, Edison, NJ (US);
Stuart B. Rosenblum, West Orange, NJ (US);
Joseph A. Kozlowski, Princeton, NJ (US);
Yuefei Shao, Princeton, NJ (US);
Brian F. Mcguinness, Plainsboro, NJ (US);
Douglas W. Hobbs, Yardley, PA (US);
Seong Heon Kim, Livington, NJ (US);
Gopinadhan N. Anilkumar, Edison, NJ (US);
Michael K. C. Wong, North Brunswick, NJ (US);
Qingbei Zeng, Edison, NJ (US);
Stuart B. Rosenblum, West Orange, NJ (US);
Joseph A. Kozlowski, Princeton, NJ (US);
Yuefei Shao, Princeton, NJ (US);
Brian F. McGuinness, Plainsboro, NJ (US);
Douglas W. Hobbs, Yardley, PA (US);
Schering Corporation, Kenilworth, NJ (US);
Pharmacopeia Drug Discovery, Inc., Princeton, NJ (US);
Abstract
The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.